Ashok Bhandari

Protagonist Therapeutics (United States) — United States

Medicine · Health Sciences

5h-index105citations16works20.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(5), Immunodeficiency and Autoimmune Disorders(5), Psoriasis: Treatment and Pathogenesis(4), Immunotherapy and Immune Responses(3), Cell Adhesion Molecules Research(3)

Publications16 total

JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans
Scientific Reports·2024· 20 citedOpen Access
S1028 Characterization of a First-in-Class Oral Therapy Selectively Targeting the IL-23 Pathway
The American Journal of Gastroenterology·2023
Regulation of Iron Homeostasis and Efficacy of Rusfertide Analog Peptide in a Mouse Model for Polycythemia Vera
Blood·2021· 5 cited
Hepcidin Peptidomimetics - Oral Efficacy in Pre-Clinical Disease Model of Iron Overload
Blood·2020· 4 cited
730 Safety, Pharmacokinetics, and Pharmacodynamics of the Novel Oral Peptide Therapeutic PN-10943 (alpha4beta7 Integrin Antagonist) in Normal Healthy Volunteers
The American Journal of Gastroenterology·2019· 3 cited
The Biomarker Profile of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor, Tracks with Efficacy in a Preclinical Model of IBD
Gastroenterology·2017· 4 cited
P-271 The Biomarker Profile of PTG-200, an Oral Peptide Antagonist of IL-23 Receptor, Correlates with Efficacy in Preclinical Models of IBD
Inflammatory Bowel Diseases·2017
P001 The biomarker profile of PTG-200, an oral peptide antagonist of IL-23 receptor, tracks with efficacy in a preclinical model of IBD
Journal of Crohn s and Colitis·2017· 5 citedOpen Access
Clustering of disulfide-rich peptides provides scaffolds for hit discovery by phage display: application to interleukin-23
BMC Bioinformatics·2016· 12 citedOpen Access
P-148 Discovery of Novel Oral Peptide Antagonists of IL-23 Receptor that Are Efficacious in a Rat Model of IBD
Inflammatory Bowel Diseases·2016· 2 citedOpen Access
P-126 PTG-100, An Oral Peptide Antagonist of Integrin α4β7 that Alters Trafficking of Gut Homing T Cells in Preclinical Animal Models
Inflammatory Bowel Diseases·2016· 8 citedOpen Access
Additional file 2: of Clustering of disulfide-rich peptides provides scaffolds for hit discovery by phage display: application to interleukin-23
Figshare·2016Open Access
Additional file 1: of Clustering of disulfide-rich peptides provides scaffolds for hit discovery by phage display: application to interleukin-23
Figshare·2016Open Access
ジスルフィドに富むペプチドのクラスタ化はファージディスプレイによるヒット発見のためのスカフォードを提供する:インターロイキン‐23への応用
2016
Discovery and Characterization of a Potent Interleukin-6 Binding Peptide with Neutralizing Activity In Vivo
PLoS ONE·2015· 42 citedOpen Access
O-022 Integrin α4β7
Inflammatory Bowel Diseases·2014

Frequent Co-authors

Xiaoli Cheng(12), Herodion Celino(8), Larry Mattheakis(6), Mark L. Smythe(5), David Liu(5), Roopa Taranath(5), Genet Zemede(4), Thamil Annamalai(4), Dinesh Patel(4), Jaimee McMahon(3), Tran T. Tran(3), Gregory T. Bourne(3), David Liu(3), Keith Huie(3), David T. Barkan(3), Charles S. Craik(3), Andrej Săli(3), Bai Lu(3), Vinh Tran(3), Brian Frederick(3)